This protocol covers adults aged 18 years and over with erysipelas where the infection is located near the eyes or nose — including periorbital cellulitis — and who have no penicillin allergy.
Infection in the facial danger zone — around the eyes, or in the triangle from the bridge of the nose to the corners of the mouth — carries a higher concern due to the risk of a serious intracranial complication. Specialist advice should be considered in this setting.
A combination antibiotic (co-amoxiclav) is recommended as the first-choice agent for this scenario. The appropriate route of administration is determined by the person's clinical condition — the complete dosing schedule, duration, route selection criteria, and monitoring requirements are detailed in the full protocol.
Symptoms are expected to begin improving within 2 to 3 days. Full resolution of symptoms at 5 to 7 days is not expected — skin takes time to return to normal after erysipelas.